1 withdrawn. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Withdrawn 1 |
Follow NAFLD: new trials by email Literature Review of NAFLD trials Research Report on NAFLD
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Assessment of the Safety of Foralumab, an Oral Anti-CD3 Antibody, in Patients With NASH and T2DM Foralumab, placebo, Omeprazole 20mg - NASH - Nonalcoholic Steatohepatitis, NAFLD | Phase 2 | Withdrawn | Tiziana Life Sciences LTD | 2017-12-01 | 2019-09-12 |
Diabetes Mellitus, Type 2 (1) · Non-alcoholic Fatty Liver Disease (1)
Diabetes Mellitus (1) · Digestive System Diseases (1) · Endocrine System Diseases (1) · Fatty Liver (1) · Glucose Metabolism Disorders (1) · Liver Diseases (1) · Metabolic Diseases (1) · Nutritional and Metabolic Diseases (1)
Muromonab-CD3 (1) · Omeprazole (1) · foralumab (1)